Q-omics provides the consensus-scored ZYG11B profile across patient tissues and cancer cell-line models. ZYG11B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZYG11B is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, ZYG11B RNA expression shows 21,221 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where ZYG11B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZYG11B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZYG11B survival associations across molecular data types. ZYG11B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZYG11B RNA expression–survival associations across cancer types. High ZYG11B expression shows unfavorable associations in BLCA, but favorable associations in KIRC, HNSC, COAD, UCS and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZYG11B RNA expression.
This table summarizes ZYG11B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZYG11B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZYG11B shows lower tumor expression in COAD, BRCA, LUSC, THCA, READ and KIRP. The COAD box plot shows higher ZYG11B RNA expression in normal versus tumor tissue (log2 FC = −0.549, t-test p < 0.001).
This table shows molecular features associated with ZYG11B in patient tissues and cancer cell lines. In patient samples, ZYG11B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZYG11B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
